His work has led to the development of a novel method for propagating precursors of human arterial cells which could potentially be used for drug discovery and has given the Vereide Group the ability to model key events during cardiovascular disease. Their persistent work to establish successful propagation techniques for dendritic cells holds great promise for the advancement of a powerful immunotherapy (wherein a patient’s own immune system is directed against cancer cells). And in the exciting wide-open field of organogenesis, Dave Vereide and the Vereide Group are doing the heavy lifting required to lay the foundation of knowledge necessary for generation of complex tissues and organs, ultimately to be used in clinical applications.
I am captivated by the fact that human embryonic stem cells are intrinsically immortal: given the appropriate culture conditions they can self-renew indefinitely. The work of multiple researchers over the past several decades indicates that these cells are immortal because they are governed at the molecular level by a core set of factors that maintain them in their pluripotent state. I hypothesize that this paradigm applies to many other types of progenitor cells. Thus, by elucidating and manipulating the core factors that govern particular progenitor states, we can enable the culture of many types of progenitors, which can then be used for basic research, for drug screening, and for cell-based regenerative therapies. Currently, I am focused on the identification and culture of progenitors of blood and vascular tissues.
Areas of Expertise
- Stem cell biology
Ph.D. Cancer Biology, 2009, University of Wisconsin-Madison
B.S. Biological Sciences, 2003, University of Alaska-Anchorage
2011-2013 NIH Ruth L. Kirschstein National Research Service Award 5T32HG002760 Genomic Sciences Training Program
2007-2009 National Cancer Center Predoctoral Fellowship
2004-2005 NIH Ruth L. Kirschstein National Research Service Award T32 CA009135-30
- Vereide D, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A, Hammerschmidt W, and Sugden B. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene, 33(10):1258-64. PMCID: PMC3690170. March 2014. Epub March 2013.
- Vereide D and Sugden B. Lymphomas differ in their dependence on Epstein-Barr virus. Blood, 117(6):1977-85. PMCID: PMC3056644. February 2011. Epub November 2010.
- Vereide D and Sugden B. Insights into the evolution of lymphomas induced by Epstein-Barr virus. Advances in Cancer Research, 108:1-19. 2010. Review.
- Vereide D and Sugden B. Proof for EBV’s sustaining role in Burkitt’s lymphomas. Seminars in Cancer Biology, 19(6):389-93. PMCID: PMC2789873. December 2009. Epub July 2009. Review.